Joshi Shashank R, Kale Shailaja, Oomman Abraham, Joshi Romesh M, Chopra Dimple
Lilavati & Bhatia Hospital, Mumbai.
J Indian Med Assoc. 2005 Jul;103(7):392, 394-6.
Although there has been widespread dissemination of knowledge about hypertension, it remains poorly treated in most populations. Systemic hypertension is associated with increased risk for coronary artery disease, stroke, nephrosclerosis, peripheral vascular disease, etc. The treatment of hypertension includes non-pharmacological measures and the specific drug therapy. Losartan potassium is an orally active, non-peptide angiotensin II receptor antagonist. It is the first of this new class of drugs introduced for clinical use in hypertension. Data was obtained of 347 patients from 140 general physicians. The study revealed that losartan potassium is used in the treatment of mild to moderate hypertension with excellent to good response in 98.8% of the cases. Mild adverse reactions were reported in 5.8% of the cases. None of the adverse reactions were severe enough which required discontinuation of therapy or needed hospitalisation. Thus, the present postmarketing surveillance study confirms the safety and efficacy of losartan potassium in Indian population.
尽管关于高血压的知识已广泛传播，但在大多数人群中其治疗情况仍不容乐观。系统性高血压与冠状动脉疾病、中风、肾硬化、外周血管疾病等风险增加相关。高血压的治疗包括非药物措施和特定的药物治疗。氯沙坦钾是一种口服活性非肽类血管紧张素II受体拮抗剂。它是这类新型药物中首个被引入用于高血压临床治疗的药物。从140名普通内科医生处获取了347例患者的数据。该研究表明，氯沙坦钾用于治疗轻至中度高血压，98.8%的病例有良好至极佳的反应。5.8%的病例报告有轻度不良反应。没有不良反应严重到需要停药或住院治疗。因此，当前的上市后监测研究证实了氯沙坦钾在印度人群中的安全性和有效性。
